Skip to main content

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 541646. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 47307, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/731165/Champions-Oncology-to-Announce-Second-Quarter-Financial-Results-on-Tuesday-December-13-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.41
-3.62 (-1.63%)
AAPL  257.97
-4.80 (-1.83%)
AMD  229.07
-8.96 (-3.76%)
BAC  50.80
-0.72 (-1.39%)
GOOG  254.50
+3.16 (1.26%)
META  730.99
-2.28 (-0.31%)
MSFT  522.34
+4.68 (0.90%)
NVDA  179.04
-2.12 (-1.17%)
ORCL  272.30
-2.85 (-1.04%)
TSLA  432.75
-9.85 (-2.23%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.